FLERIE Flerie AB (publ)

1.223USD12.40 SEK · STO-2.36%Mkt Cap: 109.27M USDP/E: —

Flerie AB (publ) is a venture capital firm specializing in early-stage investments. The firm seeks to invest in life science, biotech and pharma companies engaged in drug development and associated tools or applications …

Key Statistics

Company
Market Cap109.27M USD
Enterprise Value80.03M USD
Revenue (TTM)256.38K USD
Gross Profit-1.87M USD
Net Income (TTM)-74.64M USD
Revenue/Share0.0028 USD
Last Price1.223 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees8
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0022447348
Valuation
P/E (Trailing)—
P/E (Forward)-30.24
PEG—
EV/EBITDA-24.37
EV/Revenue312.14
P/S426.20
P/B0.35
EPS (TTM)-1.11 USD
EPS (Forward)-0.04 USD
52W Range
1.2130% of range3.464
52W High3.464 USD
52W Low1.213 USD
Profitability
Gross Margin0.00%
Oper. Margin-1280.77%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-22.41%
ROA-22.28%
ROIC-1.12%
ROCE-0.94%
Growth
Revenue Growth0.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.77M USD
CapEx (TTM)—
FCF Margin4828.87%
FCF Yield11.33%
Net Debt-25.98M USD
Net Debt/EBITDA7.91
Net Debt/FCF-2.10
Balance Sheet
Debt/Equity0.00
Current Ratio7.05
Quick Ratio4.17
Book Value/Sh3.54 USD
Cash/Share0.30 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split8:7
Split DateMay 15, 2026
Analyst Consensus
Rating—
Target (Mean)2.169 USD
Upside (mean)+77.4%
Target Range2.169 USD – 2.169 USD
# Analysts1
Ownership
Shares Out.89.36M
Float22.43M
Insiders32.99%
Institutions14.91%
Technical
SMA 501.509 (-19.0%)
SMA 2002.146 (-43.0%)
Beta-0.26
S&P 52W Chg8.68%
Avg Vol (30d)76.40K
Avg Vol (10d)49.76K
Technical Indicators
RSI (14)26.0
MACD-0.7151
MACD Signal-0.7773
MACD Hist.+0.0622
BB Upper1.459 USD
BB Middle1.313 USD
BB Lower1.168 USD
BB Width22.13%
ATR (14)0.0607 USD
Vol Ratio (20d)0.50x

About Flerie (STO: FLERIE)

›

Flerie (STO: FLERIE) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 8 employees.

The shares were at 12.40 SEK on 20 November 2026, down 63.1% over 52 weeks. Its 52-week range is 12.30 SEK to 35.13 SEK, and it trades at the bottom of that range.

Its market capitalisation is 1.11B SEK.

Flerie reports return on equity of -22.4% and flat revenue year over year.

It holds more cash than debt, a net cash position of 263.50M SEK. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 22.00 SEK is 77.4% above the current price.